{"entity":{"id":"nct04829604","kind":"trial","name":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","aka":[],"tldr":"A phase 2 trial of ARX788 in HER2-positive breast cancer, run by Ambrx, Inc., active and no longer recruiting.","summary":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) is a phase 2 interventional study registered as NCT04829604 by Ambrx, Inc., with 72 participants enrolled, started 2021-10-26 and due to reach its primary completion in 2026-12. Interventions recorded: ARX788.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04829604","url":"https://clinicaltrials.gov/study/NCT04829604"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["arx788"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04829604","phase":"2","setting":"A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd","sponsor":"Ambrx, Inc.","enrolled":72,"outcomes":[]},"route":"/trials/nct04829604/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/"}]}}